Global Immunomodulator Market

The global immunomodulator market accounted for USD 233.03 billion in 2023 and is expected to reach USD 477.55 billion by 2034 with a CAGR of 6.74% during the forecast period 2024-2034. Increased research and development activities, a focus on personalized medicine, the rising prevalence of immunological disorders, patient preference for biologic therapies, and technological advancements in drug development will all propel the market's expansion.

Improved safety and efficacious characteristics of new immunomodulatory medications are being produced as a result of biotechnology and immunology developments. Improved patient results can be achieved by using these next-generation medications, which provide a more focused approach to immune system regulation. For instance, Merck has experience with immunomodulatory treatments, especially with cancer medications such as Keytruda (pembrolizumab).

By product, the immunosuppressants segment accounted for the highest revenue-grossing segment in the global immunomodulator market in 2023 owing to the growing demand for immunosuppressants in organ transplantation and autoimmune disease treatment, as well as their established use in preventing transplant rejection and managing inflammatory conditions. For instance, Prometheus Biosciences, Inc. was acquired by Merck in June 2023 as part of an agreement to expand its business into immunology and other relevant areas where high-value patient therapies are provided. Additionally, the immunostimulants segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing focus on boosting the immune response against infectious diseases, cancer, and emerging pathogens, alongside advancements in immunotherapy and vaccine development.

By application, the oncology segment accounted for the highest revenue-grossing segment in the global immunomodulator market in 2023 owing to the growing adoption of immunomodulatory therapies, such as immune checkpoint inhibitors and cytokine therapies, for the treatment of various cancers, leading to improved patient outcomes and expanded market share. For instance, Eli Lilly and Company announced in June 2023 that they were purchasing DICE Therapeutics, Inc. This acquisition will hasten the pace of innovation in autoimmune disease treatment. Additionally, the respiratory diseases segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising prevalence of respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and lung infections, driving the demand for immunomodulatory therapies to manage inflammation and enhance respiratory function.

By end-user, the hospital's segment accounted for the highest revenue-grossing segment in the global immunomodulator market in 2023 owing to the increasing adoption of immunomodulatory therapies in hospital settings for the treatment of various diseases, alongside the availability of specialized healthcare facilities and skilled medical professionals. For instance, Sun Pharma introduced CEQUA, a calcineurin inhibitor immunomodulator, as a dry eye treatment in Canada in January 2022. The product makes use of nano micellar (NCELL) technology to increase the physicochemical stability and bioavailability of cyclosporine, thereby facilitating its penetration into the ocular tissue. Additionally, the homecare segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising demand for convenient and cost-effective healthcare solutions, coupled with advancements in homecare technologies and patient preferences for managing chronic conditions in the comfort of their homes.

North American region is anticipated to have the highest revenue share during the forecast period owing to the presence of strong economic infrastructure, technological advancements, and a robust consumer base. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the large and growing economies, increasing urbanization, and government investment in infrastructure and technology. For instance, Novartis's Cosentyx (secukinumab) was designated by the FDA as a breakthrough medicine to treat hidradenitis suppurativa. on January 25, 2024

This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.

Report Scope:

• Base Year: 2023
• Forecast Period: 2024-2034
• Study Coverage
• Market Forecast by Product, Application, and End-User
• Market Forecast for 5 Regions and 17+ Countries
• North America (U.S. and Canada)
• Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
• Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
• Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
• MEA (South Africa, GCC, Rest of MEA)
• Exhaustive Company Profiles of the Top 10+ Major Market Players

Segmentation: Immunomodulator Market Report 2023 - 2034

Immunomodulator Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)

• Immunosuppressants
• Immunostimulants

Immunomodulator Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)

• Oncology
• Respiratory
• HIV
• Others

Immunomodulator Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)

• Hospitals
• Homecare
• Specialty Clinics
• Others

Immunomodulator Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)

• North America
• U.S.
• Canada
• Europe
• Germany
• France
• UK
• Spain
• Italy
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of APAC
• Latin America
• Brazil
• Mexico
• Argentina
• Rest of LATAM
• Middle East & Africa
• South Africa
• GCC
• Rest of MEA